In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why EPO Matters

Executive Summary

Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.
Advertisement

Related Content

Can Amgen Find a New Engine?
Regional EPO Deals: Large vs. Small Molecules
Regional EPO Deals: Large vs. Small Molecules
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Roche and Amgen Watched in Challenge over EPO
Roche and Amgen Watched in Challenge over EPO
FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Biosimilars: The Time Has Come
Biosimilars: EMEA Wants Approvals
Biosimilars: EMEA Wants Approvals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel